SCHEMBL7645937

SCHEMBL7645937

Fc1cccc(SCCCN2CCc3ccccc3C2)c1

nearest known ligand 0.75

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 7/20 0.75
DRD2 P14416 7/20 0.75
HTR2A P28223 7/20 0.75
HTR7 P34969 7/20 0.75
DRD3 P35462 7/20 0.75
HTR2B P41595 7/20 0.75
KDM4E B2RXH2 2/20 0.61
ALDH1A1 P00352 2/20 0.61
HTR5A P47898 1/20 0.55
HRH1 P35367 3/20 0.54
SLC6A4 P31645 2/20 0.52
LMNA P02545 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
PRMT5 O14744 1/20 0.51
WDR77 Q9BQA1 1/20 0.51
MAPT P10636 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ATM Q13315 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7647354 0.86 HTR1A (1.00) HTR1ADRD2HTR2AHTR7DRD3
Ammonia Solution, Strong SCHEMBL7650889 0.85 HTR1A (0.97) HTR1ADRD2HTR2AHTR7DRD3
Hydrochloric Acid SCHEMBL20359058 0.85 HTR1A (1.00) HTR1ADRD2HTR2AHTR7DRD3
SCHEMBL7647211 0.76 DRD2 (0.82) HTR1ADRD2HTR2AHTR7DRD3
SCHEMBL7647774 0.74 HTR7 (0.55) HTR1ADRD2HTR2AHTR7DRD3
SCHEMBL7646838 0.73 DRD2 (0.76) HTR1ADRD2HTR2AHTR7DRD3
SCHEMBL28992933 0.72 HTR1A (0.60) HTR1ADRD2HTR2AHTR7DRD3
SCHEMBL20364968 0.71 HTR5A (1.00) HTR1ADRD2HTR2AHTR7DRD3
SCHEMBL10035538 0.71 HTR7 (0.77) HTR1ADRD2HTR7SLC6A4PRMT5
Hydrochloric Acid SCHEMBL20359282 0.70 HTR1A (1.00) HTR1ADRD2HTR2AHTR7DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6486173-B2 SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-26 US claimed
US-20010041714-A1 5-HT7 receptor antagonists CAIN GARY A (US) 2001-11-15 US claimed
US-6239143-B1 TREATMENT CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, SLEEP DISORDERS, AND SCHIZOPHRENIA. DUPONT PHARMACEUTICALS COMPANY 2001-05-29 US claimed
US-6486173-B2 SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-26 US disclosed
US-20010041714-A1 5-HT7 receptor antagonists CAIN GARY A (US) 2001-11-15 US disclosed
US-6239143-B1 TREATMENT CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, SLEEP DISORDERS, AND SCHIZOPHRENIA. DUPONT PHARMACEUTICALS COMPANY 2001-05-29 US disclosed
WO-2000000472-A1 5-HT7 RECEPTOR ANTAGONISTS DU PONT PHARMACEUTICALS COMPANY (US) 2000-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041714-A1 5-HT7 receptor antagonists HTR7, HTR5A, HTR1A HTR1A 3/4885DRD2 100/4885HTR2A 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.